Related references
Note: Only part of the references are listed.Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
Matteo Piccini et al.
JOURNAL OF CLINICAL MEDICINE (2021)
A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
Jia Yin et al.
FRONTIERS IN ONCOLOGY (2021)
Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen
Qingyu Xu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
Bhavana Bhatnagar et al.
LEUKEMIA & LYMPHOMA (2020)
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study
Yinjun Lou et al.
LEUKEMIA RESEARCH (2020)
Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study
Lixin Wang et al.
CLINICAL EPIGENETICS (2020)
Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia
Jiayu Huang et al.
LEUKEMIA & LYMPHOMA (2018)
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia A retrospective cohort study
Jun Xu et al.
MEDICINE (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy
Y. Lun et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
R. F. Schlenk et al.
LEUKEMIA (2017)
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells
Yin Li et al.
CLINICAL EPIGENETICS (2017)
Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine
Xia Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Prithviraj Bose et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
How I treat acute myeloid leukemia presenting with preexisting comorbidities
Yishai Ofran et al.
BLOOD (2016)
A prognostic model for survival after salvage treatment with FLAG-Ida plus /- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
Juan M. Bergua et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Paul Ferguson et al.
HAEMATOLOGICA (2016)
Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia
Thomas B. Alexander et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Paul Ferguson et al.
HAEMATOLOGICA (2016)
How I treat refractory and early relapsed acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2015)
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
Xuejie Jiang et al.
ONCOTARGET (2015)
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
Jianyong Li et al.
ONCOTARGET (2015)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Share Paper
